ScreenerHero

LEGN Legend Biotech Corporation

NAS · US · Healthcare · Biotechnology · legendbiotech.com
18.71USD-2.14%Mkt Cap: 3.64B $P/E: —

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the Unit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap3.64B USD
Enterprise Value2.94B USD
Revenue (TTM)1.27B USD
Gross Profit620.80M USD
Net Income (TTM)-296.80M USD
Revenue/Share6.86 USD
Last Price18.71 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)17.83
PEG—
EV/EBITDA-70.70
EV/Revenue2.31
P/S2.86
P/B2.95
EPS (TTM)-0.52
EPS (Forward)1.05
52W Range
16.2412% of range37.46
52W High37.46 USD
52W Low16.24 USD
Profitability
Gross Margin60.34%
Oper. Margin14.89%
EBITDA Margin-3.27%
Profit Margin-28.85%
ROE-29.62%
ROA-17.12%
Growth
Revenue Growth51.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-100.20M USD
CapEx (TTM)28.60M USD
FCF Margin2.14%
FCF Yield0.75%
Net Debt-686.40M USD
Net Debt/EBITDA16.50
Balance Sheet
Debt/Equity0.41
Current Ratio3.04
Quick Ratio2.88
Book Value/Sh6.35 USD
Cash/Share4.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)46.50 USD
Upside (mean)+148.5%
Target Range24.00 USD – 74.00 USD
24.00+148.5% to mean74.00
# Analysts13
Ownership
Shares Out.194.49M
Float193.54M
Insiders1.86%
Institutions56.85%
Short Interest
Short Ratio7.4d
Short % Float17.80%
Short % Out.7.53%
Shares Short14.64M
Short (prev mo.)17.82M
Technical
SMA 5019.78 (-5.4%)
SMA 20022.39 (-16.4%)
Beta0.57
S&P 52W Chg16.45%
Avg Vol (30d)2.02M
Avg Vol (10d)2.11M
Technical Indicators
RSI (14)44.2
MACD-0.4613
MACD Signal-0.5828
MACD Hist.+0.1215
BB Upper19.94 USD
BB Middle18.79 USD
BB Lower17.65 USD
BB Width12.18%
ATR (14)0.9247 USD
Vol Ratio (20d)0.95x